Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma

Conditions: Multiple Myeloma

Sex: All

Ages: 18 Years – 99 Years

Enrollment: 33

Sponsor: Odense University Hospital

Location: Denmark

Summary

Pirmary endpoint: to examine the feasibility of using an mHealth app for reporting of side effects instead of a telephone call from the hospital staff together with examining the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before. With this innovative method investigator aimed to give the patient more independence in their daily life and in that way improve their quality of life.

Eligibility Criteria

Inclusion Criteria:patients with MM scheduled for Bortezomibpatients should have access to a smartphonepatients should be able to self-report side effects of Bortezomib using a smartphone app, and be willing to participate in a semi-structured interview.Exclusion Criteria:patients had to talk and read danish

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05724966). StuddyBuddy aggregates publicly available trial information.